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Abstract
Hematopoietic stem cells (HSC) promptly adapt hematopoi-
esis to stress conditions, such as infection and cancer, replenishing
bone marrow–derived circulating populations, while preserving
the stem cell reservoir. SOCS2, a feedback inhibitor of JAK–STAT
pathways, is expressed in most primitive HSC and is upregulated
in response to STAT5-inducing cytokines. We demonstrate that
Socs2 deﬁciency unleashes HSC proliferation in vitro, sustaining
STAT5 phosphorylation in response to IL3, thrombopoietin, and
GM-CSF. In vivo, SOCS2 deﬁciency leads to unrestricted myelo-
poietic response to 5-ﬂuorouracil (5-FU) and, in turn, induces
exhaustion of long-term HSC function along serial bone marrow
transplantations. The emerging role of SOCS2 inHSCunder stress
conditions prompted the investigation of malignant hematopoi-
esis. High levels of SOCS2 characterize unfavorable subsets of
acute myeloid and lymphoblastic leukemias, such as those with
MLL and BCR/ABL abnormalities, and correlate with the enrich-
ment of genes belonging to hematopoietic and leukemic stemness
signatures. In this setting, SOCS2 and its correlated genes are part
of regulatory networks fronted by IKZF1/Ikaros and MEF2C, two
transcriptional regulators involved in normal and leukemic
hematopoiesis that have never been linked to SOCS2. Accord-
ingly, a comparison of murine wt and Socs2/ HSC gene expres-
sion in response to 5-FU revealed a signiﬁcant overlap with the
molecular programs that correlate with SOCS2 expression in
leukemias, particularly with the oncogenic pathways and with
the IKZF1/Ikaros and MEF2C-predicted targets. Lentiviral gene
transduction ofmurine hematopoietic precursors withMef2c, but
not with Ikzf1, induces Socs2 upregulation, unveiling a direct
control exerted by Mef2c over Socs2 expression. Cancer Res; 75
(11); 2387–99. 2015 AACR.
Introduction
Hematopoiesis is a regulated process in which bone marrow
multipotent hematopoietic stem cells (HSC) are driven toward
self-renewal or differentiation (1). At the steady state, long-term
HSC (LT-HSC) remain mostly quiescent and rarely divide to
produce short-term HSC (ST-HSC), multipotent precursor
(MPP), and committed progenitors (2), ensuring a continuous
ﬂow of differentiated hematopoietic cells. Under hematopoietic
stress, such as infections, traumata, myeloablation, and cancer,
HSC on one side proliferate to reconstitute the affected hemato-
poietic pools or expand speciﬁc hematopoietic populations such
as myeloid-derived suppressor cells in the presence of cancer; on
the other side, even in conditions of emergency hematopoiesis,
they do need to maintain the stem cell reservoir (3, 4).
HSC quiescence, activation, self-renewal, and differentiation
under bone marrow stress are regulated by cytokines (5), includ-
ing stem cell factor (SCF), IL3, thrombopoietin (TPO), erythro-
poietin (EPO), Flt3/Flk2 ligand (Flt3L), GM-CSF, G-CSF, and IL6.
Signal transduction of most hematopoietic cytokines passes
through the Janus-activated kinase (JAK) and signal transducer
and activator of transcription (STAT; ref. 5). Suppressor of cyto-
kine signaling (SOCS) family comprises eight members (SOCS1-
7 and CIS) with similar structures, which are induced upon JAK/
STAT activation and function as negative feedback. SOCS1 and
SOCS3 immunologic roles are widely recognized (6, 7). SOCS2
has been initially described as a regulator of the growthhormone–
insulin-like growth factor 1 axis (8, 9) and only recently has been
recognized as controller of immunologic functions (10–12).
SOCS2 basal expression is higher in HSC (particularly LT-HSC)
than in differentiated populations (13–16), and it is upregulated
following STAT5 activation by hematopoietic cytokine stimula-
tion (17) or following myeloablative 5-ﬂuorouracil (5-FU) treat-
ment (18). Induction of Socs2 by G-CSF, IL3, GM-CSF, and EPO
1Molecular Immunology Unit, Department of Experimental Oncology
and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei
Tumori, Milan, Italy. 2Department of Human Pathology, University of
Palermo, Palermo, Italy. 3Hematopathology Section, Department
of Hematology and Oncology, S. Orsola-Malpighi Hospital, University
of Bologna, Bologna, Italy. 4Functional Genomics Core Facility, Fon-
dazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Note: Supplementary data for this article are available at Cancer Research
Online (http://cancerres.aacrjournals.org/).
M.P. Colombo and C. Tripodo share senior authorship of this article.
Corresponding Author:Mario P. Colombo, Molecular Immunology Unit, Depart-
ment of Experimental Oncology and Molecular Medicine, Fondazione IRCCS
Istituto Nazionale dei Tumori, Via Amadeo 42, 20133 Milan, Italy. Phone: 39-02-
23902252; Fax: 39-02-23903073; E-mail:
mariopaolo.colombo@istitutotumori.mi.it
doi: 10.1158/0008-5472.CAN-14-3625




has been documented in cell lines and tissues, including the bone
marrow (19).
In hematologicmalignancies (20–22), the JAK–STAT pathways
are frequently deregulated (10, 11), with oncogenic activation of
STAT3 and STAT5 in acute myeloid leukemia (AML), and of
STAT1 and STAT5 in pre-B acute lymphoblastic leukemia (B-ALL)
and chronicmyelogenous leukemia (CML; ref. 20), with potential
involvement of SOCS2.
Here, we have uncovered a novel role for SOCS2 in the
regulation of HSC functions in settings of bone marrow myelo-
poietic stress response and, by thorough analysis of SOCS2
expression in human hematopoietic malignancies, we have iden-
tiﬁed SOCS2 deregulation as part of a stemness-relatedmolecular




Socs2/ mice were obtained from Dr. C. Farquharson [The
Roslin Institute and Royal (Dick) School of Veterinary Studies,
University of Edinburgh, Roslin, United Kingdom] and back-
crossed to C57BL/6NCrl for 10 generations. Six- to 8-week-old
age- and sex-matchedwild-type (wt) and Socs2/ littermateswere
used for experiments. C57BL/6NCrl mice were purchased from
Charles River. CD45.1 mice were bred in our animal facility.
Experimentswere performed according to local ethical guidelines.
5-FU myeloablation
Mice were injected intraperitoneally with 150 mg/kg body
weight of 5-FU (TEVA). White blood cells (WBC) were counted
on blood samples collected in heparinized tubes and counts were
expressed as WBC/mL of blood.
Cell preparation and bone marrow assays
Bone marrow cells were ﬂushed from tibias and femurs and
spleens were mechanically disrupted in PBS and passed through
70-mm cell strainers (BD). Erythrocytes were lysed and remaining
cells were resuspended in PBS. For puriﬁcation of bone marrow
lineage-negative cells (Lin), we used mouse lineage cell deple-
tion kit (Miltenyi Biotec) following the manufacturer's instruc-
tions. Details about serial bone marrow transplantation (BMT)
experiments, in vitro colony-forming cell assay, in vitro cytokine
stimulation, FACS, and phospho-STAT5 staining are included in
the Supplementary Methods.
Histopathology and IHC
Histopathologic analyses on mouse tissues were performed on
sections stained with hematoxylin and eosin. IHC on human
bonemarrowwas performed as previously described (23) using a
speciﬁc anti-human SOCS2 antibody (Abcam). Detailed descrip-
tion of the analyzed human bone marrow samples is provided in
the Supplementary Methods.
Human public dataset analysis
For computational gene expression proﬁles (GEP) analyses,
public human leukemia datasets were used. Detailed information
about samples and methods used for analysis are included in the
Supplementary Data.
Microarray
For gene expression experiment, wt and Socs2/ LincKitþSca-
1þ (LKS) from 6mice/group were individually sorted in TRIzol as
described in the Supplementary Data. Bead Chip Array Mou-
seWG-6 v2 (Illumina) was used for transcriptome analysis.
Detailed procedures used for RNA extraction, cDNA ampliﬁca-
tion, microarray, data preprocessing, and analysis are included in
the Supplementary Data. Gene expression data are deposited in
NCBI's Gene Expression Omnibus database (accession number
GSE66065).
Lentiviral production and infection of Lin cells
The pReceiver-Lv215 lentiviral vectors containing the full-
length open reading frame (ORF) cDNA of mouse Mef2c
(NM_001170537) and Ikzf1 (NM_001025597) or the empty
vector were purchased from GeneCopoeia. A third-generation
packaging system involving the transfection of four plasmids in
the producer cells, namely two packaging plasmids (pMDLg/
pRRE and pRSV-REV), an envelope plasmid (pMD2-VSV-G),
and the lentiviral transfer vector, was used. Lentiviral stocks
were produced in 293T cells by Ca3PO4 cotransfection of the
four plasmids. Supernatants were collected, passed through a
0.22-mm ﬁlter, and puriﬁed by ultracentrifugation as described
previously (22). Lin cells isolated from wt mice were prestimu-
lated overnight in Stemspan SFEM (STEMCELL Technologies)
supplemented with 100 ng/mL SCF, 100 ng/mL Flt3L, 50 ng/mL
TPO, 20 ng/mL IL3, and then lentiviral particles were added at a
multiplicity of infection (MOI) of 100. After 24 hours, cells were
washed and cultured without the cytokine cocktail; for positive
control, untransduced cells were left in the presence of cytokines;
48hours later, cellswere collected and lysed in TRIzol andused for
subsequent analysis.
Statistical analysis
Data in the histograms of Figs. 1–4 and 6 were represented as
mean  SEM, and an unpaired two-tailed Student t test was
routinely calculated otherwise speciﬁed in the ﬁgure legends.
Results
Hematopoietic stress responses are deregulated in SOCS2-
deﬁcient mice
Expression of Socs2 in HSC under basal conditions was high in
LKS multipotent HSC and declined in lineage-committed com-
mon myeloid progenitors (CMP), granulocyte/monocyte pro-
genitors (GMP), andmegakaryocyte/erythroid progenitors (MEP;
Supplementary Fig. S1A and S1B), consistent with Socs2 charac-
terizing the stem cell compartment (13–16, 22, 25). Still, SOCS2
was dispensable for basal hematopoiesis being the bone marrow
composition of wt and Socs2/ mice similar at the steady state
(Supplementary Fig. S1C and S1D). We hypothesized that
SOCS2, as inhibitor of JAK–STAT signaling, could inﬂuence HSC
functions in settings of hematopoietic stress. Therefore, we stud-
ied the bonemarrow response tomyeloablation induced by 5-FU
in wt and Socs2/ mice. After 5-FU, a wave of cytokines is
produced and induces bone marrow regeneration, which occurs
around day 10 (3, 21). Socs2was rapidly induced in bonemarrow
Lin cells (a population enriched for HSC) 1 day after 5-FU
administration and reached 30-fold upregulation after 6 days of
treatment, returning to baseline within day 10 (Fig. 1A). Follow-
ing 5-FU treatment, WBC counts similarly reached nadir within 4
days, but Socs2/mice fully recoveredbetweenday7 and9,while
wtmice recovered at day 11, a time point at which Socs2/WBC
counts even exceeded baseline (Fig. 1B). At day 14, Socs2/mice
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displayed splenomegaly (Fig. 1C) and increased bone marrow
cellularity (Fig. 1D) especially in the granulocytic compartment,
suggesting an unrestrained myelopoietic response. Histologic
analysis conﬁrmed greater expansion of granulocytes and mega-
karyocytes in Socs2/ than in wtmice at day 7 and 14 after 5-FU
(Fig. 1E).
The excessive expansion of differentiated hematopoietic popu-
lations in response to 5-FU treatment in Socs2/ mice was
Figure 1.
SOCS2 limits HSC response to 5-FU. A, qPCR of Socs2 in bonemarrow Lin cells frommice at the indicated time points showed transient increase of Socs2 soon after
5-FU treatment (5 mice/each time point). B, WBC counts following 5-FU treatment showed accelerated and unrestrained rebound in Socs2/ compared
withwtmice. C, splenomegaly occurred in Socs2/mice after 5-FU. D, whole bone marrow and CD11bþGr1þ cell counts from one femur 14 days after 5-FU revealed
the overwhelming expansion of bone marrow cells in Socs2/ mice. E, histologic analysis of bone marrow sections of mice 7 and 14 days after 5-FU treatment
showed increased expansion of megakaryocytic and granulocytic elements in Socs2/ mice. F and G, absolute cell numbers of the indicated bone marrow
populations in mice treated with 5-FU indicated that expansion of committed progenitors was evident in Socs2/ mice upon treatment. Results are shown
as ratio of counts from treated animals compared with the mean absolute number of three untreated mice of the same strain. H, relative frequency of LT-HSC
(CD150þCD48), ST-HSC (CD150þCD48þ), andMPP (CD150CD48þ) showed increased frequency of committed progenitors at the expense of LT-HSC. Results of 5-
FU experiments are from three independent experiments (n ¼ 7 treated mice and n ¼ 3 untreated mice/group).
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consequence of LKS,CMP,GMP, andMEPampliﬁcation (Fig. 1F),
whichoutnumbered theirwt counterpart. Further characterization
of LKS using SLAM markers CD48/CD150 showed that the
unrestricted expansion of LKS in the absence of SOCS2 was
conﬁned to ST-HSC and MPP progenitors (Fig. 1G) with reduced
LT-HSC relative frequency (Fig. 1H).
SOCS2 is induced upon cytokine signaling and in turn controls
cytokine-mediated HSC expansion
SOCS2 induction was observed in patients treated with
hematopoietic cytokines. In normal bone marrow, SOCS2
marked hematopoietic precursors lining the bone trabeculae (Fig.
2A, left, black arrows) and scattered immature precursors, whereas
SOCS2 stained expanded erythroid,myeloid, andmegakaryocytic
precursor clusters (black arrows) in bone marrow from patients
treated with EPO and G-CSF (Fig. 2A, middle) or TPO (Fig. 2A,
right).
Inmice, TPO, IL3, andGM-CSF strongly induced Socs2, whereas
SCF, G-CSF, Flt3L, IL6, and EPOwere negligible Socs2 inducers in
bone marrow Lin cells (Fig. 2B).
To explore the role of SOCS2 in HSC following cytokine
stimulation, we cultivated wt or Socs2/ LKS for 3 days in the
Figure 2.
SOCS2 is upmodulated and regulates
HSC functions upon cytokine
stimulation. A, bone marrow sections
from patients treated with EPOþG-
CSF or TPO stained for SOCS2 show
upregulated SOCS2 compared with
control healthy bone marrow (scale
bars, 100 mm, top; 50 mm, bottom).
B, Lin cells sorted from bone
marrow of a pool of wt animals were
stimulated with SCF, Flt3L, G-CSF,
EPO, IL6, TPO, GM-CSF, and IL3 and
the expression of Socs2was evaluated
at the indicated time points by qPCR.
Graphs are representative of two to
four experiments. C, 104 LKS sorted by
ﬂow cytometry were cultivated
with the following cytokines: IL3
(10 ng/mL), IL6 (10 ng/mL),
SCF (20 ng/mL), TPO (20 ng/mL), and
Flt3L (20 ng/mL); after 3 days, cells
were counted; histograms show
absolute numbers normalized to the
mean of absolute numbers of the
corresponding untreated controls;
results are representative of four
experiments and indicated that
Socs2/ LKS displayed an increased
proliferative response to cytokines
compared with wt counterpart.
D, CFU-C from wt and Socs2/ bone
marrow (n ¼ 8) showed enhanced
colony formation in the absence of
SOCS2.
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presence of IL3, IL6, SCF, Flt3L, and TPO cytokine cocktail, or
of each single cytokine, and measured the LKS expansion.
Socs2/ LKS proliferative response to the cocktail, as well as
to IL3 alone, exceeded that of wt LKS (Fig. 2C). Moreover, when
cultivated in methylcellulose-based medium containing SCF,
IL3, IL6, and EPO, Socs2/ bone marrow cells produced higher
numbers of colony-forming units (CFU) than the wt counter-
part (Fig. 2D). Altogether, these results demonstrate that
SOCS2 induction by cytokine stimulation limits HSC prolifer-
ative response.
SOCS2 controls STAT5 signaling in vitro and in vivo
Considering that STAT5 signaling is activated by TPO, IL3, and
GM-CSF and promotes HSC self-renewal (26) and that, according
to motif gene sets fromMSigDB collection, SOCS2 promoter (2
kb,þ2kbaround transcription start site) contains putative STAT5A
Figure 3.
SOCS2 controls STAT5 signaling in vitro and in vivo. A–C, total bone marrow cells isolated from wt and Socs2/ mice were starved in complete medium with no
serum for 2 hours prior to stimulation with the indicated cytokines for the indicated times. Nonstimulated samples were collected for each time point. Cells
were then ﬁxed immediately, and stained for surface antigens and for phospho-STAT5. Phospho-STAT5 expression in gated LKS (A), CMP/GMP cells
(linc-kitþSca-1CD34þ; B), and MEP (linc-kitþSca-1CD34; C) was evaluated. Mean ﬂuorescence intensity (MFI) relative to unstimulated control samples
are plotted in the graphs on the left and representative histograms are shown on the right. The stimulation with each cytokine was repeated in three independent
experiments, each with three mice/group. D, LT-HSC (linc-kitþSca-1þCD34Flt3), ST-HSC (linc-kitþSca-1þCD34þFlt3), MPP (linc-kitþSca-1þCD34þFlt3þ),
and linc-kitþSca-1 were sorted from bone marrow of wt and Socs2/ mice 6 days after 5-FU treatment and qPCR for the indicated probes were performed.
Results are from three independent sorting replicates, each starting from a pool of 6 mice for untreated and 10 mice for 5-FU–treated samples and demonstrate
that SOCS2 is able to limit the transcription of STAT5 target genes induced upon 5-FU treatment.
SOCS2 in Stress-Adapted and Leukemic Hematopoiesis
www.aacrjournals.org Cancer Res; 75(11) June 1, 2015 2391
Figure 4.
Transient enhancement and long-term exhaustion of HSC function in serial BMT in the absence of SOCS2. A, Socs2 was transiently upregulated in Lin bone
marrow cells following BMT as revealed by qPCR (5 mice/group). B, histologic examination of bone marrow sections 10 weeks after I BMT showed enhanced
repopulation of bone marrow cells in Socs2/ compared with wt bone marrow recipients. C, bone marrow cells from one femur were counted by two
operators 10 weeks after each BMT and averaged. D, engraftment of I, II, and III BMT recipients of Socs2/ bone marrow was enhanced, as evaluated by FACS as
percentage of CD45.2þ cells in blood samples. E, higher frequency of LKS and linc-KitþSca-1 precursors in mice receiving Socs2/ bonemarrow. F, bonemarrow
recovered from recipients receiving Socs2/ bone marrow formed higher numbers of CFU-C; G, reduced survival of IV BMTmice receiving Socs2/ bone marrow;
results are pooled from three independent experiments with a total number of 17 mice/group; statistical signiﬁcance was calculated with the log-rank test. H, loss of
reconstitution ability in the absence of SOCS2 in IV BMT recipients at the indicated times. (Continued on the following page.)
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but not STAT1, STAT3, STAT4, STAT5B, and STAT6 motifs (Sup-
plementary Table S1),wehypothesized that SOCS2 could function
as a negative feedback for STAT5 signaling in HSC upon TPO, IL3,
or GM-CSF stimulation. Inwt LKS, TPO, IL3, andGM-CSF induced
rapid phosphorylation of STAT5, peaking 15 minutes after stim-
ulation and rapidly declining to baseline within 120minutes (Fig.
3A, solid line; refs. 27, 28). Differently, in Socs2/ LKS, STAT5
phosphorylationwas enhanced and persisted beyond120minutes
following stimulationwith TPOor IL3 (Fig. 3A, dotted line), while
a slight anticipationofSTAT5phosphorylationoccurreduponGM-
CSF stimulation. Enhanced STAT5 phosphorylation was also evi-
dent in Socs2/ CMP/GMP in response to TPO and GM-CSF,
whereas only slight differences were induced by IL3 (Fig. 3B). In
MEP, only TPO induced phospho-STAT5 but no differences were
found between wt and Socs2/ genotypes (Fig. 3C).
We subsequently tested whether deregulated STAT5 signaling
occurred in vivo in response to 5-FU, accounting for the increased
myelopoietic response. LT-HSC, ST-HSC, MPP, and LK Sca-1
were sorted from wt and Socs2/ bone marrow 6 days after 5-FU
administration and the expression of the STAT5 target genes (23)
Pim2, Il2ra, and Ccn3/Nov was evaluated (17). In the absence of
SOCS2, the expression of Pim2 and Il2ra was higher in ST-HSC,
MPP, and LincKitþSca-1 and that of Ccn3/Nov in ST-HSC (Fig.
3D). Interestingly, no differences were observed in LT-HSC, again
suggesting that SOCS2 inﬂuences differentiating precursors rather
than primitive HSC.
Altogether, these results indicate that in HSC, SOCS2 acts as a
negative regulator of STAT5 signaling.
SOCS2deﬁciency enhances transientHSC repopulating activity
and causes exhaustion of long-term hematopoietic stemness
Considering that HSC proliferation and stemnessmaintenance
are inversely correlated programs, we analyzed the impact of
SOCS2deﬁciency in the setting of repeated bonemarrowhemato-
poietic stress adopting serial BMT. These experiments would let us
evaluate whether the augmented expansion of ST-HSC and MPP
andnot of LT-HSCobserved in Socs2/mice under 5-FUpressure
could result in the impairment of LT-HSC functions. According to
the upregulation of Socs2 in hematopoietic precursor in settings of
bone marrow stress, Socs2 was transiently upregulated in Lin
bone marrow cells following BMT (Fig. 4A).
To perform serial BMT, two cohorts of lethally irradiated
(CD45.1) mice received 1  106 total bone marrow cells from wt
or Socs2/ littermates (CD45.2). Ten weeks after primary BMT (I
BMT), bone marrow cells from the chimeric mice were retrans-
planted into secondary (IIBMT) lethally irradiatedhosts (CD45.1).
The same procedure was adopted for tertiary and quaternary
transplants (III and IV BMT).
Consistent with enhanced stress response of Socs2/HSC, the
repopulation of bone marrow hematopoietic parenchyma eval-
uated histologically after the I BMT was signiﬁcantly enhanced in
Socs2/ bone marrow recipients than wt recipients (Fig. 4B), as
well as the degree of myelopoiesis within the splenic red pulp
(Supplementary Fig. S2). Bone marrow cellularity (Fig. 4C) and
bone marrow engraftment (Fig. 4D), assessed as percentage of
circulating donor-derivedCD45.2þ cells 10weeks after BMT,were
higher in mice receiving Socs2/ bone marrow compared with
mice receiving wt bone marrow in I, II, and III BMT. These effects
were associated to higher frequencies of LKS and LincKitþSca-1
precursors (Fig. 4E) and with enhanced in vitro colony-forming
capacity in recipients of Socs2/ bone marrow than of wt coun-
terpart (Fig. 4F). Within the LincKitþSca-1 subset, the distri-
bution of CMP, GMP, and MEP was conserved in the two groups
of mice (Supplementary Fig. S3).
Enhanced hematopoietic responses observed in mice receiving
Socs2/ bonemarrow in BMT from I to III, in turn, resulted in the
exhaustion of LT-HSC repopulating potential in the IV BMT,
which caused reduced survival of mice receiving Socs2/ bone
marrow comparedwith those receivingwtbonemarrow (Fig. 4G).
Such failure in bonemarrow hematopoiesis was associated with a
lower fraction of circulating donor hematopoietic cells
(CD45.2þ), particularly of the CD11bþ compartment (Fig.
4H). Further conﬁrming the loss of repopulating potential of
Socs2/ bone marrow at the IV BMT, bone marrow histopathol-
ogy on long-term survivals (300 days after IV BMT) revealed
hypocellular marrow with scant foci of residual hematopoiesis
inmice receiving Socs2/ bonemarrow in comparison withmice
receiving wt bone marrow, which showed a more conspicuous
bone marrow repopulation and diffuse hematopoietic cellularity
(Fig. 4I, top). Consistently, the spleen red pulp of IV BMT with
Socs2/ donor bone marrow showed hemorrhagic appearance
with foci of hemosiderin deposition underlining the failure of the
splenic hematopoiesis, which was preserved in recipients of wt
bone marrow (Fig. 4I, bottom).
The experiments with 5-FU indicated that in the absence of
SOCS2 LKS, speciﬁcally the committed progenitors ST-HSC and
MPP were expanded with consequent reduction in relative fre-
quency of LT-HSC (see Fig. 1). Also in III BMT recipients receiving
Socs2/ bone marrow, the increased frequency of LKS associated
with expanded MPP and/or ST-HSC populations and with
reduced frequency of LT-HSC, and this result was valid using
both the SLAM markers and CD34/FLT3 to identify the popula-
tions (Fig. 4J). Such contraction of the LT-HSC compartment in
mice receiving Socs2/ bone marrow was progressively acquired
along with the series of transplantations, with signiﬁcant differ-
ences in LT-HSC frequencies starting from the II BMT (Fig. 4K).
Therefore, the absence of SOCS2 caused initial enhanced bone
marrow reconstitution by deregulated expansion of ST-HSC/
MPP, with exhaustion of long-term hematopoietic stemness
resulting in decreased survival of IV BMT recipients of Socs2/
bone marrow.
SOCS2 upregulation in human hematopoietic malignancies
identiﬁes unfavorable acute leukemia subsets
Hematopoietic stemness and differentiation programs are pro-
foundly altered in hematopoietic malignancies, which develop
from genetic aberrancies in a setting of a disrupted hematopoietic
homeostasis. Following the demonstration that SOCS2 plays a
(Continued.) Results are representative of three experiments (n¼ 6/group). I, histologic examination of long-time survivors of IV BMT showing severe bonemarrow
loss and splenic populations in Socs2/ compared with wt bone marrow recipients. J, representative plot and relative frequency of LT-HSC, ST-HSC,
and MPP calculated using CD34/Flt3 (top) or CD150/CD48 (bottom) in III BMT recipients of Socs2/ bone marrow 10 weeks after BMT. K, the same analysis using
SLAM markers is shown for I BMT and II BMT recipients 10 weeks after transplantation. All results are expressed as mean and SEM and are representative
of four independent experiments (n ¼ 7/group).
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role in regulating hematopoietic stress responses and in preserv-
ingHSC stemnessmaintenance in vivo, we challenged the hypoth-
esis that its expression could be deregulated in human hemato-
poietic malignancies. Analyzing public GEP, we found signiﬁcant
differences in SOCS2 expression in human hematopoietic neo-
plasms with different degree of differentiation, namely
CML, myelodysplastic syndromes (MDS), AML, and ALL
(ANOVA, P < 0.001), with SOCS2 levels peaking in some AML
and inmost ALL cases (Fig. 5A). These resultswere conﬁrmedby in
situquantitative immunolocalization analysis of SOCS2 (Fig. 5B).
Speciﬁcally, in normal bone marrow, SOCS2 stained progenitors
populating para-trabecular areas and myeloid precursors in the
interstitium of the inter-trabecular areas (Fig. 5C, black arrows).
No or faint expression was detected inmature cells (blue arrows).
In CML, SOCS2 expression was increased in the expanded mye-
loid precursors (black arrows) and decreased in clusters of dif-
ferentiated myeloid elements (blue arrows). In MDS, character-
ized by ineffective hematopoiesis of the neoplastic clone, SOCS2
marked immature precursors also showing abnormal localization
(black arrows), whereas in AML and ALL, it was expressed in the
blastic population effacing the bone marrow. Thus, the levels of
both SOCS2 transcript and protein were associated with the
immature precursor populations expanding at the expense of the
effective hematopoietic pool.
Considering SOCS2 heterogeneity, we analyzed how SOCS2
expression was modulated in each leukemic subtype. In CML,
SOCS2 mRNA and protein (Supplementary Fig. S4) increased
along progression from chronic phase toward accelerated phase
and blast crisis.
In AMLpatients, high levels of SOCS2 characterized cloneswith
speciﬁc cytogenetic lesions such as those with MLL (11q23) and
BCR/ABL1 (t9:22) lesions, which share a dismal prognosis (Fig.
5D). Consistently, elevated SOCS2 levels correlated with reduced
overall survival (OS) inAMLpatients (Fig. 5E), alsowithin subsets
of AML with normal karyotype enriched in clones with FLT3-ITD
and associated with poor prognosis (Fig. 5F).
In ALL, high SOCS2 characterized more immature subsets,
namely c-ALL/pre-B-ALL or pro-B-ALL, whereas levels of SOCS2
closer to that of normal bone marrow were detected in more
mature B-ALL and in T-ALL (Fig. 5G). Grippingly, also in ALL, the
same subsets with unfavorable cytogenetics, namely those with
MLL abnormalities and those characterized by BCR/ABL1, dis-
played the highest levels of SOCS2 (Fig. 5H).
SOCS2 marks a stemness-related program in acute leukemias
and is part of IKZF1/Ikaros and MEF2C regulatory networks
AML-associated HSC and leukemic stem cell (LSC) signatures
have been recently described and related to bad prognosis (29).
Considering that the basal expression of SOCS2 is conﬁned to
primitive HSC and that the upregulated SOCS2 expression char-
acterized unfavorable acute leukemias, we hypothesized that
SOCS2 could be part of a stemness program in acute leukemias.
To this aim, we generated a list of genes positively correlated with
SOCS2 in acute leukemias (Supplementary Table S2) and cross-
matched the list with the AMLHSC/LSC signature (29).We found
a high degree of overlap between the two gene lists (P < 0.001; Fig.
6A) and the shared genes, namely TRAF3IP2, MEF2C, FRMD4B,
BCL11A, COL5A1, ELK3, ERG, PTK2, SPTBN1, and ARPP-19,
corresponding to 32 probe sets, were used to generate a more
restricted gene list of "leukemic stemness- and SOCS2-associated
gene list" (Table 1).
Unsupervised clustering of acute leukemia samples according to
this restricted gene list was suitable to group acute leukemias with
SOCS2 levels above (or below) the median value (SOCS250–100),
comprising most ALL and a small subgroup of AML (Fig. 6B).
Speciﬁcally within AML samples, cases characterized by MLL
(11q23) and t(15;17) cytogenetic lesions formed deﬁned clusters
associated with high or low SOCS2, respectively (Fig. 6C). Simi-
larly, within ALL samples, the "leukemic stemness- and SOCS2-
associated gene list" pinpointed patients with E2A/PBX1 translo-
cation and low SOCS2 expression and patients with MLL or BCR/
ABL aberrations and high SOCS2 expression (Fig. 6D).
We also interrogated the list of SOCS2-related genes to identify
common regulatory networks shared by SOCS2 and its correlates.
Following the hypothesis that deregulated SOCS2 expression
could depend on STAT5 activation, we searched for known STAT5
targets identiﬁed in HSC (17, 30). More speciﬁcally, only two of
the 99 SOCS2 correlates belonged to STAT5-predicted targets (Fig.
6E) according to C3 motif genesets collection of MSigDB (Sup-
plementary Table S1), suggesting that upregulated SOCS2was not
a mere bystander result of JAK2–STAT5 activation.
Rather, we noted that several SOCS2 best correlates, including
CTGF, MEF2C, DNTT, CD79B, ADD3, CD24, LIG, BLNK, and
SOCS2 itself, were predicted or validated target genes of the
transcriptional factor IKZF1/Ikaros, which plays key roles in
normal hematopoiesis and B-cell lymphopoiesis (31) and that
is involved in AML (32), ALL (33) and CML blast crisis (34).
Moreover, MEF2C, encoding the transcription factor myocyte
enhancer factor 2C (MEF2C), is one of the best correlates of
SOCS2 and is also a target of Ikaros.MEF2Chas similar expression
pattern of SOCS2 in normalHSC (35) and is ectopically expressed
in MLL-rearranged AML (36). Therefore, we evaluated whether a
regulatory network existed involving SOCS2, Ikaros and/or
MEF2C in acute leukemias by ARACNe reverse engineering anal-
ysis (37). We determined transcriptional networks of IKZF1/
Ikaros and MEF2C in bone marrow myeloid and lymphoid
precursors, AML and ALL, and identiﬁed genes whose expression
was signiﬁcantly related with them; these genes were deﬁned as
"ﬁrst neighbors" of the network representing putative transcrip-
tional targets of IKZF1/Ikaros andMEF2C (Supplementary Tables
S3 and S4). Of note, SOCS2 was one of the ﬁrst neighbor of both
IKZF1/Ikaros and MEF2C (Supplementary Tables S3 and S4) in
normal HSC and acute leukemias, but not in mature B cells, and
relatedmalignancies (non-Hodgkin lymphomas), conﬁrming the
speciﬁcity of these molecular interactions in hematopoietic pre-
cursor malignancies (Supplementary Tables S5 and S6). MEF2C
was a target of IKZF1/Ikaros sharing with IKZF1 a network of 530
targets (Supplementary Fig. S5). Among the SOCS2 correlates that
were identiﬁed as ﬁrst neighbors, 84 of 87 IKZF1/Ikaros putative
targets were also MEF2C targets, whereas other 90 genes were
exclusively MEF2C targets (Fig. 6F and G), suggesting a more
direct dependency of SOCS2 on MEF2C.
Common SOCS2-correlated programs are engaged in human
acute leukemias and in in vivo experimental HSC stress
Prompted by in situ analyses of human acute leukemias reveal-
ing the link between SOCS2 and, primarily, MEF2C, we investi-
gated whether such link exists also in a condition of hematopoi-
etic stress in vivo. To this aim, we generated GEP of murine LKS
sorted from wt and Socs2/ bone marrow 6 days after 5-FU
treatment. Supervised comparison revealed 51 differently
expressed genes (DEG) with a fold change 2 and P < 0.001
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Figure 5.
High expression of SOCS2
characterizes unfavorable acute
leukemia subsets. A, analysis of
SOCS2 using public GEP datasets of
normal bonemarrow, MDS, CML, AML,
and ALL samples revealed
upregulated SOCS2 levels in
leukemias compared with normal
bone marrow. Box plot with quartiles,
minimum, and maximum values are
shown; the Benjamini–Hochberg
correction was applied and statistical
analysis was performed using a one-
way ANOVA. B, ImageJ quantiﬁcation
of in situ expression of SOCS2 in bone
marrow samples from normal bone
marrow, MDS, CML, AML, and ALL;
statistical analysis was performed
using a one-way ANOVA; each
pathologic condition was also
compared with normal bone marrow
with an unpaired t test. C,
representative images of in situ
expression of SOCS2 in bone marrow
samples from normal bone marrow,
MDS, CML, AML, and ALL; scale bars,
50 mm. D, higher SOCS2 levels
corresponded to the unfavorable AML
subset carrying t(11q23)/MLL and
t(9;22) karyotypes; boxes and
statistics are calculated as above. E,
the Kaplan–Meier analysis of OS of
AML patients according to SOCS2
expression, grouped in quartiles. High
SOCS2 expression correlated with
poorer OS; statistical analysis was
performed using the log-rank test. F,
the same analysis as in E was applied
to AML cases with normal karyotype.
G, higher expression of SOCS2 in ALL
identiﬁed more immature subgroups
(pro–B- or pre–B-ALL) rather than
mature B- and T-ALL. H, expression of
SOCS2 in ALL cases according to the
karyotype; box plot and statistics are
calculated as above.
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Figure 6.
In acute leukemias, SOCS2 and its
correlated stem cell signature cluster
speciﬁc subtypes and are part of
regulatory networks independent
from STAT and dependent on Ikaros
and MEF2C. A, Venn diagram showing
signiﬁcant overlap between SOCS2
correlated genes and AML stemness-
related genes. B, unsupervised
hierarchical clustering of AML and ALL
samples according to the gene list
indicated in Table 1 showed clear
enrichment of ALL cases and of a
subset of AML cases in the group
with higher SOCS2 expression
(Socs250–100). LYP, lymphoid
precursor, MYP, myeloid precursors.
C, the same analysis, applied to AML
samples subdivided according to
cytogenetic lesions, was able to
identify MLL- and t(15;17)-rearranged
samples expressing high and low
SOCS2, respectively. D, the same
analysis as in panel B for ALL samples
clustered subsets with MLL and E2A/
PBX1 lesions within high and low
SOCS2 groups, respectively. E, Venn
diagram showing the lack of STAT5
potential targets within the SOCS2
correlated gene list; the Fisher exact
test was used for statistical analysis. F,
regulatory network of two
transcription factors Ikaros and
MEF2C as deﬁned by ARACNe
algorithm on top 100 genes sorted by
mutual information score. Each gene is
represented by a green triangle and
each interaction is represented by a
black line. G, Venn diagram showing
signiﬁcant overlaps between IKZF1/
Ikaros network, MEF2C network, and
SOCS2-related genes; the Fisher exact
test was used for statistical analysis. H,
Venn diagram showing the overlap of
IKZF1/Ikaros ﬁrst neighbors, MEF2C
ﬁrst neighbors, and 51 genes
differently expressed in Socs2/
versus wt murine LKS 6 days after 5-
FU treatment; the Fisher exact test
was used for statistical analysis. I,
murine bone marrow Lin cells were
infected with the lentiviral vectors
containingMef2c and Ikzf1ORF orwith
empty vector as negative control and
qPCR was performed for Socs2;
noninfected cells were included in the
analysis as negative control and Lin
cells grown in the presence of the
cytokine cocktail were used as
positive control of Socs2 induction.
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(Supplementary Table S7). Among them, eight were upregulated
and 43 were downregulated in Socs2/ as compared with wt
counterpart.
In the absence of SOCS2, there was a positive enrichment of
gene sets encoding for proteins involved in the translational
machinery, in line with a more active metabolism of Socs2/
LKS in response to myeloablation, whereas among the pathways
negatively enriched in Socs2/ LKS,many had relevance in cancer
and others were linked to cytokine response (Supplementary
Table S8 and Supplementary Fig. S6).
We then investigated similarities between gene programs
differentially regulated in human leukemias according to
SOCS2 gene expression and the 51 DEG of murine LKS under
hematopoietic stress. We documented a signiﬁcant correspon-
dence between the cellular programs enriched in the two
signatures as deﬁned by GSEA. In particular, 10 "curated
genesets" (Supplementary Table S9) and 7 "oncogenic signa-
tures" (Supplementary Table S10) were enriched using the 51
DEG and 2 out of 10 of the former and seven out of eight of the
latter categories were also enriched considering SOCS2-corre-
lated genes in human leukemias (Supplementary Tables S9 and
S10, yellow highlights).
Moreover, considering the 79 probe sets corresponding to the
36 out of 51murine DEG that are detectable in the human arrays,
33 were MEF2C putative targets identiﬁed by reverse engineering
in human acute leukemias (corresponding to 11 genes), and only
8of these 33probe sets (corresponding to SOCS2 itself andPATZ1
genes) were also IKZF1/Ikaros ﬁrst neighbors (Fig. 6H).
Collectively, human reverse engineering and murine GEP
results were strongly indicative that MEF2C could be a key
regulator of SOCS2 expression in HSC in different setting, while
suggesting a less prominent or indirect role for Ikaros. To conﬁrm
this potential mechanism, we lentivirally transduced murine
bone marrow Lin with Mef2c and Ikaros ORF and conﬁrmed
the expression of the two transcripts by qPCR (Supplementary Fig.
S7). The overexpression of MEF2C was able to signiﬁcantly
upregulate Socs2 transcription, similarly to the induction medi-
ated by cytokine cocktail stimulation, whereas Ikaros expression
was unable to affect the transcription of Socs2. Therefore, in HSC,
the expression of Socs2, besides being regulated by cytokine
stimulation, is also controlled by MEF2C.
Discussion
HSC self-renewal and differentiation in response to hemato-
poietic stress are regulated by cytokines signaling through JAK–
STAT pathways (38). Our report describes for the ﬁrst time
the active role of SOCS2 in regulating HSC functions during
nonhomeostatic conditions such as bone marrow stress or malig-
nant hematopoiesis. In this setting, we have identiﬁed a new
regulatory mechanism inducing Socs2 independently from STAT
pathways while depending on MEF2C.
As negative regulator of the JAK2–STAT5 pathway, SOCS2
keeps in check stress-induced HSC response avoiding uncon-
trolled ampliﬁcation of ST-HSC, MPP, and committed precursors
thus preserving long-term hematopoiesis. Accordingly, we dem-
onstrate that SOCS2 deﬁciency is associated with aberrant expan-
sion of hematopoietic progenitors following 5-FUmyeloablation
and with the impoverishment of the stem cell pool in response to
serial BMT. Indeed, SOCS2 deﬁciency enhanced bone marrow
reconstitution in I, II, and III BMT recipients and, eventually, loss
of long-term hematopoietic function, with decreased survival of
IV BMT recipients. This was related with the composition of the
LKS pool that in Socs2/ bone marrow chimeras was character-
ized by higher ST-HSC andMPP but reduced LT-HSC frequencies.
SOCS2 is overexpressed in primitive HSC (13–16) compared
withmore differentiated populations, both inhuman (13–16 and
mouse (22, 25), suggesting that basal SOCS2 expression could
contribute to stemness maintenance. Nevertheless, Hansen and
colleagues (25) published that Socs2-deﬁcient mice had normal
reconstitution capacity in primary and secondary competitive
BMT experiments. Our kinetic analysis of Socs2 expression fol-
lowing the bone marrow myeloablation (BMT or 5-FU) clearly
indicated that SOCS2 overexpression and SOCS2-negative regu-
lation of STAT5 are transient and occur within 1 day after mye-
loablative treatment. Of note, the analysis of bone marrow
composition reported by Hansen and colleagues (25) was per-
formed 4 weeks after BMT, a time point at which bone marrow
homeostatic hematopoiesis is restored.
We have dissected in vitro the dominant mechanism exerted by
SOCS2overHSCexpansion: in conditions of hematopoietic stress
or upon triggering with IL3, TPO, or GM-CSF, SOCS2 is tran-
siently upregulated and primarily tunes JAK2–STAT5 activation, a
pathway known to regulate cytokine-mediated HSC response
(39) and self-renewal (26). Increased SOCS2 expression occurs
also in bone marrow of patients treated with hematopoietic
cytokines, suggesting a clear connection in hematopoietic cyto-
kine response between mice and humans. However, we cannot
exclude that in HSC other cytokines and/or other STATs could be
regulated by SOCS2, nor that other SOCS family members, such
as the known STAT5 regulators SOCS1 and SOCS3, could play
Table 1. Gene list of SOCS2 best correlates associated to stemness
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redundant roles (6).Other pathways are also activatedbyhemato-
poietic cytokines such as the phosphatidylinositol-3-kinase
(PI3K)pathway and themitogen activatedprotein kinase (MAPK)
pathway. Thismultiplicity of checkpoints is necessary tomaintain
bone marrow integrity and suggests that the differences observed
in our experiments, although statistically signiﬁcant, might be
attenuated by redundancy of the system.
Altered Socs2 expression has emerged from GEP of several
hematologic malignancies. In CML patients, upregulated SOCS2
was found in CD34þ cells during the transition from the chronic
phase to the blast phase and has been associated with poor
prognosis (40, 41). In contrast, a mouse model of BCR/ABL1–
induced CML shows the same incidence regardless SOCS2 deﬁ-
ciency (25). However, these data cannot be considered conclusive
given that suchmodel is characterized by a short latency and rapid
progression, representing a suboptimal setting to appreciate any
potential phenotype related with SOCS2 effects.
The signiﬁcance of SOCS2 modulation in hematologic malig-
nancies other than CML, includingMDS, AML, and ALL has never
been thoroughly addressed. Our data conﬁrm SOCS2 upregula-
tion along different CMLblast-enrichment phases, and document
for the ﬁrst time that SOCS2 increased expression characterizes
speciﬁc AML and ALL subsets with unfavorable BCR/ABL or MLL
lesions and with the mixed lineage phenotype, a feature of
aberrant hematopoietic stemness. Of interest, ALL and SOCS2
have never been associated before. In AML, we could also dem-
onstrate that high SOCS2 levels correlate with poor prognosis. At
themolecular level, SOCS2 and the coregulated genes signiﬁcant-
ly overlapped with those belonging to AML-associated HSC and
LSC signatures (29).
In patients carrying mutations and translocations associated
with constitutive activation of JAK2/STAT5, such as BCR-ABL or
FLT3-ITD, high SOCS2 possibly reﬂects the chronic phosphory-
lation of STAT5. Accordingly, the expression of SOCS2 is down-
regulated inCMLpatientswithBCR-ABL following treatmentwith
the tyrosine kinase inhibitor imatinib (42), andpatients refractory
to the treatment displayed higher SOCS2 compared with treat-
ment-sensitive ones (41). Similarly, in AML patients carrying the
FLT3-ITD mutation, induction of SOCS1, SOCS2, and SOCS3 is
linked with STAT5 activation, in line with the concept of SOCS2
functioning as a negative regulator of FLT3 (43).
Our reverse engineering analysis for the ﬁrst time suggests a
novel SOCS2 regulatory network that is independent from STAT
activation and that involves primarily MEF2C and less consis-
tently Ikaros. At the steady state, MEF2C and SOCS2 expression
patterns are overlapping, being high in LKS and CMP and down-
regulated in GMP and MEP; in hematologic diseases, MEF2C
upregulation is described for AML with MLL lesions (those
associated to highest SOCS2), where it contributes to confer
stemness features (35). Ikaros is a transcriptional regulator that
controls key events for lymphoid differentiation in MPP and its
dominant-negative isoforms or deletions have been reported in
cases of infant and childhood ALL (44, 45) as well as in blast crisis
of Philadelphia positive CML (34). Interestingly, GEP analysis of
MEF2C competent versus deﬁcient MPP indicated a direct rela-
tionship between MEF2C and Ikaros (46); however, such rela-
tionship has never been identiﬁed in acute leukemias neither it
has been associated with SOCS2. Our GEP analyses clearly indi-
cate that SOCS2-related transcriptional programs and MEF2C are
functionally associated also in murine HSC under stress condi-
tions. Moreover, we experimentally demonstrated that MEF2C
expression in HSC is sufﬁcient to upregulate Socs2 even in the
absence of cytokine stimulation.
Altogether, we have uncovered that SOCS2 is part of a tran-
scriptional programwith prognostic relevance in acute leukemias,
and identiﬁedMEF2C as a novel key factor that is complementary
to STAT5 in regulating SOCS2 expression in HSC. This novel
MEF2C-mediated regulation of SOCS2 might exert a pivotal role
in the absence of cytokine stimulation, such as in HSC at the
steady state and the aberrant expression of MEF2C, SOCS2 and
the correlated genes might confer leukemic stemness features to
the neoplastic hematopoietic clones. Hence, this emerging net-
work has clinical relevance and deserves further investigation.
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